Dabigatran: a new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature
-
Marta Muñoz-Corcuera [1] ; Lucía Ramírez-Martínez-Acitores [1] ; Rosa Mª López-Pintor [1] ; Elisabeth Casañas-Gil [1] ; Gonzalo Hernández-Vallejo [2]
-
[1] Universidad Complutense de Madrid
Universidad Complutense de Madrid
Madrid, España
-
[2] MD, DDS, PhD. Professor. Department of Oral Medicine and Orofacial Surgery. Faculty of Odontology. Complutense Univer-sity. Madrid, Spain
-
- Localización: Medicina oral, patología oral y cirugía bucal. Ed. inglesa, ISSN-e 1698-6946, Vol. 21, Nº. 6 (Noviembre), 2016
- Idioma: inglés
- Enlaces
-
Resumen
Dabigatran is a newly commercialized drug that is replacing other anticoagulants in the prevention of venous thromboembolism, stroke and systemic arterial valve embolism. It acts directly on thrombin presenting in a dynamic and predictable way, which does not require monitoring these patients. Therefore, we consider the need to assess whether their use increases the risk of bleeding involved before any dental treatment.
We performed a systematic review with a bibliographic search in PubMed/Medline along with the Cochrane Library. We excluded articles dealing with all anticoagulants other than dabigatran, and works about surgical treatments in anatomical locations other than the oral cavity.
We included a total of 13 papers of which 1 was a randomized clinical trial, 9 narrative literature reviews, 1 case series, 2 clinical cases and 1 expert opinion. Because we did not obtain any properly designed clinical trials, we were unable to conduct a meta-analysis.
Currently, there is no consensus on the procedure to be followed in patients taking dabigatran. However, all authors agree to treat each case individually in accordance to the risk of embolism, postoperative bleeding and renal function. Also, it is necessary to perform minimally invasive interventions, and take the appropriate local anti-hemolytic measures.
